Orbimed Advisors LLC sold $138k of PASG
owner at Passage BIO, Inc.. 230,321 shares at an average of $0.60, traded Dec 20, 2024, filed Dec 26, 2024.
Score components
- +12Role10% owner
- +11Trade size$138k at market
- 0Share of holdings soldSold 3.0% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-24-001037, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | SOpen-market sale Common Stockindirect: See footnotes | -230,321 | $0.60 | $138k | 7,404,869 | Dec 26, 2024 |
Related signals
Other insiders at Passage BIO, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | PASGsell Passage BIO, Inc. | Kathleen Borthwick CFO | $1,686 3,183 shares | -7% | |
| 25Weak | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $241k 373,645 shares | +4% | |
| 19Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $52k 62,276 shares | -1% | |
| 20Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $77k 97,103 shares | -1% | |
| 24Weak | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $285k 456,353 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.